Full Text of PDF (345k)
Article in Japanese
Abstract
Case Report
Chronic myeloid leukemia with chylothorax due to dasatinib: a case report
Yuki Miyasaka＊ Atsushi Saito Kento Yasuda Masayuki Sasahara Mamoru Takahashi Hirofumi Chiba
Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine
＊Present address: Department of Respiratory Medicine, Tonan Hospital
ABSTRACT
Dasatinib is a second-generation oral tyrosine kinase inhibitor that is frequently used for BCR-ABL-positive chronic myeloid leukemia (CML) and for Philadelphia chromosome-positive acute lymphocytic leukemia. We experienced a rare case of a 62-year-old man who developed chylothorax following 3 years of dasatinib treatment. On reducing the dose of dasatinib from 100 mg/day to 50 mg/day, the pleural effusion stopped and the course of CML became stable. Pleural effusion is a common adverse event from dasatinib, but there are still few reports of chylothorax. This case shows that dasatinib-related chylothorax improved with dose reduction.
KEYWORDS
Dasatinib Chylothorax Chronic myeloid leukemia (CML)
Received 3 Sep 2021 ／ Accepted 3 Mar 2022
AJRS, 11(3): 156-160, 2022
Copyright © The Japanese Respiratory Society All Rights Reserved.